Ai-Tong-An-Gao-Ji / Hif1a Cancer Research Results

ATAGJ, Ai-Tong-An-Gao-Ji: Click to Expand ⟱

Features:

Ai-Tong-An-Gao-Ji (ATAGJ) is a traditional Chinese medicine (TCM) formula that has been studied for its potential anti-cancer properties. The formula is a combination of several herbs, including: Ai ( Artemisia argyi or Artemisia annua), Tong ( Polygonum multiflorum), Gao ( Glycyrrhiza uralensis), and Ji ( Astragalus membranaceus). However elsewehere it states: borneol, spina gleditsiae, pillworm, faeces trogopterori, resina draconis, and semen strychni.

a multi-ingredient traditional Chinese medicine (TCM) topical preparation (ointment/“gao”) used clinically in some settings for cancer-induced bone pain (CIBP). In the best-described accessible preclinical report, ATAGJ is formulated from borneol, spina gleditsiae, pillworm, faeces trogopterori, resina draconis, and semen strychni, and was investigated via network pharmacology plus wet-lab validation highlighting fisetin (from spina gleditsiae) as a putative active component targeting AKT. Classification: multi-component botanical/animal-derived topical TCM formula; standard abbreviation: ATAGJ.

Primary mechanisms (ranked):

AKT pathway inhibition (↓p-AKT), mechanistically linked to fisetin–AKT interaction in model systems
Hypoxia signaling suppression (↓HIF-1α) with downstream angiogenic output reduction (↓VEGF)
Antiproliferative and antimigratory effects in tumor cells (model-dependent; demonstrated in Walker 256 cells with fisetin exposure)
Analgesic phenotype in CIBP rat model (↑ mechanical pain threshold; mechanistic attribution primarily to AKT/HIF-1α axis in the cited study)

Bioavailability / PK relevance: As a topical multi-component ointment, local tissue exposure may dominate; systemic PK is not established for the full formula. If fisetin is considered a key effector, its oral use is constrained by poor aqueous solubility, rapid phase-II metabolism, and generally low bioavailability unless special formulations are used.

In-vitro vs systemic exposure relevance: The cited tumor-cell experiments used fisetin at ~10–30 μM for ~24 h, which commonly exceeds free circulating levels achievable with standard oral supplementation; translation would require either high local concentrations (e.g., topical delivery) or enhanced-bioavailability formulations.

Clinical evidence status: Preclinical animal (rat CIBP) plus in-vitro tumor-cell data supporting an AKT/HIF-1α/VEGF hypothesis. No clearly verifiable, product-specific modern RCT evidence for ATAGJ as an anticancer therapy; its described use is best framed as adjunctive symptom management (pain) rather than disease-modifying oncology treatment.

Research has shown that Ai-Tong-An-Gao-Ji may have anti-tumor and anti-inflammatory effects, and may also have the ability to induce apoptosis (cell death) in cancer cells. However, more studies are needed to fully understand the effects of this formula on cancer.

It's worth noting that traditional Chinese medicine formulas like Ai-Tong-An-Gao-Ji are often used in conjunction with conventional cancer treatments, and may be used to alleviate symptoms and improve quality of life for cancer patients.

Ai-Tong-An-Gao-Ji is a traditional Chinese medicine formulation used primarily for alleviating pain, reducing inflammation, and supporting overall well-being. While some of its individual herbal components have been investigated for antioxidant, anti-inflammatory, and potential antiproliferative properties, the formulation as a whole is not established as a stand-alone anticancer treatment in modern clinical practice. Its usage remains largely within the TCM framework—often as an adjunct to other treatments—with mechanisms of action that may include modulation of inflammatory and immune pathways, pain relief, and antioxidant protection.

Ai-Tong-An-Gao-Ji (ATAGJ) — mechanistic axes with translational context

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	AKT signaling	↓p-AKT (model-dependent); ↓proliferation signals	Unknown / not well-characterized	R	Signal suppression upstream of hypoxia/angiogenesis programs	Mechanistic emphasis is driven largely by fisetin–AKT docking + co-immunoprecipitation and downstream marker changes in the cited rat/tumor-cell systems.
2	Hypoxia response and angiogenesis	↓HIF-1α; ↓VEGF (model-dependent)	Unknown / context-dependent	R/G	Reduced hypoxia-adaptation and angiogenic output	Interpretable as secondary to AKT modulation; evidence is marker-level (protein/mRNA) in the reported models.
3	Cell growth and migration phenotype	↓colony formation; ↓EdU incorporation; ↓migration (with fisetin exposure)	Unknown	G	Antiproliferative / antimigratory phenotype	Demonstrated using fisetin (10–30 μM) in Walker 256 cells; these concentrations may be difficult to achieve systemically without formulation or local delivery.
4	Pain hypersensitivity in CIBP model	↔ (not a tumor-intrinsic axis)	↑mechanical pain threshold (analgesic phenotype in vivo)	G	Symptom relief (bone cancer pain model)	Mechanistic linkage in the study is largely inferred through the same AKT/HIF-1α marker set; broader nociceptive cytokine pathways were not the central validated axis in the accessible report.
5	Clinical Translation Constraint	↔	↔	↔	Delivery, safety, and evidence limitations	Formula complexity and batch variability; unclear human PK for the full ointment; fisetin has poor oral bioavailability without enhanced formulations; inclusion of semen strychni (maqianzi) introduces clinically important toxicity considerations (strychnine/brucine) that must be controlled/processed appropriately; limited product-specific modern clinical trial evidence.

Hif1a, HIF1α/HIF1a: Click to Expand ⟱

Source:

Type:

Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product)
-Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells
-HIF1A induces the expression of vascular endothelial growth factor (VEGF)
-High HIF-1α expression is associated with Poor prognosis
-Low HIF-1α expression is associated with Better prognosis

-Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism.
-Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis

Key mediators of aerobic glycolysis regulated by HIF-1α.
-GLUT-1 → regulation of the flux of glucose into cells.
-HK2 → catalysis of the first step of glucose metabolism.
-PKM2 → regulation of rate-limiting step of glycolysis.
-Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis.
-LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate;

HIF-1α Inhibitors:
-Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate).
-Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions.
-EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity.
-Emodin: reduce HIF-1α expression. (under hypoxia).
-Apigenin: inhibit HIF-1α accumulation.

Scientific Papers found: Click to Expand⟱

949-

FIS,

ATAGJ,

Cisplatin,

Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway

in-vivo,

BC,

Walker256

10,20,30g/day

in-vitro,

BC,

Walker256

10,20,30uM and 5uM(Cis)

indicating that the cisplatin group could substantially inhibit the migration of Walker 256 cells in both low and high dose fisetin groups

Akt↓, Hif1a↓, p‑Akt↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Death ⓘ

Akt↓, 1, p‑Akt↓, 1,

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,
Total Targets: 3

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Hif1a, HIF1α/HIF1a

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells